Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
Air purification system achieves Intertek zero ozone certification
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
According to ICMR, the upgraded OmiSure RT-PCR test for Covid-19 successfully detects all sub-types of Omicron that are currently prevalent in India
Pfizer and Moderna are also working on vaccines that target the Omicron variant
It provides Covid-19 detection and Omicron surveillance in less than two hours
Subscribe To Our Newsletter & Stay Updated
